Clinical Trial Update: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of KSQ-001EX, autologous tumor infiltrating lymphocytes engineered to inactivate SOCS1, being evaluated in select advanced solid tumors includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Lung Cancer
• Melanoma
• Solid Tumors

Drugs mentioned

• KSQ-001EX

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Solid Tumor, Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING